Canopy Growth Corporation is executing a significant operational overhaul, with recent developments highlighting its pivot toward more profitable business segments. The Canadian cannabis company has finalized a major acquisition and installed new leadership at its most successful subsidiary, marking concrete steps in its move away from past losses.
New Chapter for Vaporizer Division
Effective April 1, 2026, David Männer will assume the role of Managing Director at Storz & Bickel, the German medical vaporizer market leader. Männer is a seasoned internal candidate, having served as Deputy Managing Director for 14 years. He succeeds co-founder Jürgen Bickel, who is stepping down after building the company over a quarter-century.
Bickel’s legacy is substantial. Under his guidance, Storz & Bickel achieved a global first by obtaining ISO-13485 certification for medical vaporizers and was honored with the Dr. Rudolf Eberle Prize for technical innovation. He will remain with the company in a strategic advisory capacity.
This leadership change coincides with notable momentum for the subsidiary. According to Canopy Growth CEO Luc Mongeau, the new “VEAZY” device has become the company’s fastest-selling product ever, with 20,000 units sold in record time. The focus now shifts to accelerated product development and expanding its footprint in the United States market.
Financial Performance and Market Challenges
Operational progress is beginning to materialize in the company’s financials. For the third quarter of fiscal 2026, Canopy Growth reduced its net loss by 49% year-over-year. As of December 31, 2025, the company held approximately CAD $371 million in liquidity, bolstered by a recapitalization effort in early 2026 that extended debt maturities to 2031. Since March 2025, annualized savings of nearly $29 million have been realized.
Should investors sell immediately? Or is it worth buying Canopy Growth?
However, this recovery has yet to be fully reflected in the company’s share price. On March 26, Canopy Growth stock traded at around CAD $1.28 on the Toronto Stock Exchange. The upcoming fourth-quarter results will be a key indicator of whether the current strategy can drive sustainable market stabilization.
Strengthening the Canadian Foundation with MTL Acquisition
In a parallel strategic move, Canopy Growth completed the acquisition of MTL Cannabis on March 16, 2026. The transaction aims to establish a leading position in the Canadian medical cannabis market by revenue. MTL contributes additional production capacity for high-quality cannabis flower.
This integration is being complemented by new product launches. The company is introducing “Deep Space” infused pre-rolls to the Canadian market, which utilize liquid diamonds and THCA diamonds to achieve cannabinoid concentrations exceeding 60%. This launch represents a clear commitment to the premium product segment.
The combined effect of these initiatives—leadership stability at a high-performing unit, strategic acquisition, and premium product innovation—outlines Canopy Growth’s pathway toward improved margins and financial sustainability.
Ad
Canopy Growth Stock: Buy or Sell?! New Canopy Growth Analysis from March 29 delivers the answer:
The latest Canopy Growth figures speak for themselves: Urgent action needed for Canopy Growth investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 29.
Canopy Growth: Buy or sell? Read more here...
